ITTO20110627A1 - Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche - Google Patents

Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche

Info

Publication number
ITTO20110627A1
ITTO20110627A1 IT000627A ITTO20110627A ITTO20110627A1 IT TO20110627 A1 ITTO20110627 A1 IT TO20110627A1 IT 000627 A IT000627 A IT 000627A IT TO20110627 A ITTO20110627 A IT TO20110627A IT TO20110627 A1 ITTO20110627 A1 IT TO20110627A1
Authority
IT
Italy
Prior art keywords
methods
combination
pharmaceutical composition
metabolic disorders
treat diabetes
Prior art date
Application number
IT000627A
Other languages
English (en)
Italian (it)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITTO20110627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of ITTO20110627A1 publication Critical patent/ITTO20110627A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT000627A 2010-07-21 2011-07-15 Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche ITTO20110627A1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами

Publications (1)

Publication Number Publication Date
ITTO20110627A1 true ITTO20110627A1 (it) 2012-01-22

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000627A ITTO20110627A1 (it) 2010-07-21 2011-07-15 Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche

Country Status (30)

Country Link
US (1) US8617555B2 (enExample)
EP (2) EP2595658A2 (enExample)
JP (2) JP2013533268A (enExample)
KR (2) KR20130103486A (enExample)
CN (1) CN103118707A (enExample)
AR (1) AR082312A1 (enExample)
AU (1) AU2011281240B2 (enExample)
BR (1) BR112013001299A2 (enExample)
CA (1) CA2805961A1 (enExample)
CL (1) CL2013000200A1 (enExample)
CZ (1) CZ2013124A3 (enExample)
DE (1) DE112011102396T5 (enExample)
DK (1) DK201370089A (enExample)
EA (1) EA029847B1 (enExample)
EE (1) EE05761B1 (enExample)
ES (1) ES2445846R1 (enExample)
FI (1) FI20135152L (enExample)
FR (1) FR2962913A1 (enExample)
GB (2) GB2496799B (enExample)
IT (1) ITTO20110627A1 (enExample)
LT (1) LT5980B (enExample)
MX (1) MX2013000804A (enExample)
MY (1) MY160979A (enExample)
NO (1) NO20130265A1 (enExample)
NZ (1) NZ606964A (enExample)
PE (1) PE20130815A1 (enExample)
PH (1) PH12013500140A1 (enExample)
SE (1) SE1350212A1 (enExample)
SG (1) SG187578A1 (enExample)
WO (1) WO2012010966A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
CA2804966A1 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CN103154028A (zh) 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
WO2012007847A2 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
ITTO20110630A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
PE20130387A1 (es) 2010-07-21 2013-03-30 Oleg Iliich Epshtein Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2012007847A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
CN103154028A (zh) * 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
CA2804966A1 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
ITTO20110630A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
PE20130387A1 (es) * 2010-07-21 2013-03-30 Oleg Iliich Epshtein Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria

Also Published As

Publication number Publication date
BR112013001299A2 (pt) 2017-11-21
LT5980B (lt) 2013-12-27
PH12013500140A1 (en) 2013-03-11
FI20135152A7 (fi) 2013-02-21
GB201707872D0 (en) 2017-06-28
EA029847B1 (ru) 2018-05-31
WO2012010966A2 (en) 2012-01-26
NZ606964A (en) 2015-08-28
SG187578A1 (en) 2013-03-28
EE201300007A (et) 2013-08-15
EE05761B1 (et) 2016-03-15
JP2016222684A (ja) 2016-12-28
EP2595658A2 (en) 2013-05-29
CL2013000200A1 (es) 2015-01-23
GB2496799B (en) 2017-11-22
DE112011102396T5 (de) 2013-05-02
NO20130265A1 (no) 2013-04-18
EP3693018A1 (en) 2020-08-12
AR082312A1 (es) 2012-11-28
US20130064824A1 (en) 2013-03-14
AU2011281240B2 (en) 2016-07-07
LT2013018A (lt) 2013-10-25
KR20180127515A (ko) 2018-11-28
JP2013533268A (ja) 2013-08-22
ES2445846R1 (es) 2015-01-02
FI20135152L (fi) 2013-02-21
MY160979A (en) 2017-03-31
KR20130103486A (ko) 2013-09-23
GB2552405A (en) 2018-01-24
GB2552405B (en) 2018-05-30
FR2962913A1 (fr) 2012-01-27
ES2445846A2 (es) 2014-03-05
US8617555B2 (en) 2013-12-31
CZ2013124A3 (cs) 2013-06-12
DK201370089A (en) 2013-02-19
PE20130815A1 (es) 2013-07-18
GB201302924D0 (en) 2013-04-03
GB2496799A (en) 2013-05-22
CA2805961A1 (en) 2012-01-26
MX2013000804A (es) 2013-10-28
CN103118707A (zh) 2013-05-22
WO2012010966A3 (en) 2012-03-29
AU2011281240A1 (en) 2013-03-07
EA201300124A1 (ru) 2013-12-30
SE1350212A1 (sv) 2013-04-22

Similar Documents

Publication Publication Date Title
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
HRP20150029T1 (xx) Farmaceutski pripravak za lijeäśenje metaboliäśkog sindroma
BR112014005234A2 (pt) tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas
EP2925775A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
PL2729151T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
PL2575778T3 (pl) KOMPOZYCJE FARMACEUTYCZNE KOKRYSZTAŁÓW TRAMADOLU i KOKSYBÓW
LT3222272T (lt) Farmacinė karbetocino kompozicija
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
PL2588593T3 (pl) Kompozycje i sposoby stymulowania MAGP-1 dla poprawy wyglądu skóry
IL228090A0 (en) Compositions and methods for personal tumor profiling treatment
BR112014006321A2 (pt) composições de wnt e usos terapêuticos de tal composição
IL228030A0 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
HRP20182043T1 (hr) Upotreba anti-konfeksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
BR112014006291A2 (pt) composição e utilização da composição
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
FI20135145L (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä kardiovaskulaariseen systeemiin liittyvien tautien tai tilojen hoitamiseksi
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
IL228318A0 (en) A new derivative of octahydrothiocyanocholine, a pharmaceutical preparation containing the derivatives and their use
BR112012002353A2 (pt) uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2